Spero Therapeutics Inc. Stock News

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -12.50% and 5.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s

Provides update on ongoing FDA review of Tebipenem HBr NDA

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -12.50% and 5.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx Says FDA Committee Casts Negative Vote On ALS Drug Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)

Spero Therapeutics (SPRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Spero Therapeutics (SPRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will host a conference call and live audio webcast on Thursday, March 31, 2022,

CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will host a conference call and live audio webcast on Thursday, March 31, 2022, a

Spero Therapeutics (SPRO) reported positive results from a phase 1 trial of its antibiotic SPR206 to treat serious multi-drug resistant ((MDR)) gram-negative infections in the…

By Chris Wack Spero Therapeutics Inc. said it saw positive topline findings from its Phase 1 bronchoalveolar lavage clinical trial of SPR206, an…

SPR206 shown to be well-tolerated; achieved lung exposures consistent with predicted therapeutic levels, when administered three times daily at 100 mg

Spero Therapeutics <> said the Biomedical Advanced Research and Development Authority ((BARDA)) awarded up to an additional $12.9M to the company to to develop tebipenem as…

New award option exercised by BARDA brings the total potential funding from its existing contract with Spero up to $59.7 million New award option exercised by BARDA brings the total potential funding

Spero Therapeutics Inc (SPRO) shares closed today 10.6% higher than it did at the end of yesterday. The stock is currently down 17.6% year-to-date, down 19.8% over the past 12 months, and up 587.5% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $13.45 and as low as $11.69 this week.Shares closed 40.6% below its 52-week high and 12.9% above its 52-week low.Trading volume this week was 6.3% higher than the 10-day average and 2.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 334.8% The company's stock price performance over the past 12 months lags the peer average by -1539.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Spero Therapeutics Inc (SPRO) shares closed today 10.6% higher than it did at the end of yesterday. The stock is currently down 25.5% year-to-date, down 25.8% over the past 12 months, and up 521.4% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $13.45 and as low as $11.69 this week.Shares closed 40.6% below its 52-week high and 12.3% above its 52-week low.Trading volume this week was 12.9% higher than the 10-day average and 1.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 4.3% higher than its 5-day moving average, 4.3% lower than its 20-day moving average, and 18.1% lower than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 511.5% The company's stock price performance over the past 12 months lags the peer average by -1122.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.